Literature DB >> 22441935

Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York.

Edward L Hannan1, Zaza Samadashvili, Kimberly Cozzens, Gary Walford, Alice K Jacobs, David R Holmes, Nicholas J Stamato, Jeffrey P Gold, Samin Sharma, Ferdinand J Venditti, Tia Powell, Spencer B King.   

Abstract

BACKGROUND: Little is known about what treatments patients receive after being diagnosed with stable coronary artery disease or what the comparative outcomes are for routine medical treatment (RMT) versus percutaneous coronary intervention (PCI) with RMT for patients in a setting apart from randomized controlled trials. METHODS AND
RESULTS: Patients with stable coronary artery disease undergoing cardiac catheterization in New York State between 2003 and 2008 were followed up to determine the treatment they received. Patients receiving RMT and patients receiving PCI with RMT were propensity matched through the use of 20 factors that could have a bearing on outcomes. The resulting cohort of 933 matched pairs was used to compare mortality/myocardial infarction (MI), mortality, MI, and subsequent revascularization rates. A total of 89% of all patients underwent PCI with RMT. PCI/RMT patients had significantly lower adverse outcome rates at 4 years for mortality/MI (16.5% versus 21.2%; P=0.003), mortality (10.2% versus 14.5%; P=0.02), MI (8.0% versus 11.3%; P=0.007), and subsequent revascularization (24.1% versus 29.1%; P=0.005). Adjusted RMT versus (PCI with RMT) hazard ratios were 1.49 (95% confidence interval, 1.16-1.93) for mortality/MI and 1.46 (95% confidence interval, 1.08-1.97) for mortality. There were no differences for patients ≤ 65 years of age or for patients with single-vessel disease.
CONCLUSIONS: Most patients with stable coronary artery disease in New York undergoing catheterization between 2003 and 2008 received PCI. Patients who received PCI experienced lower mortality, mortality/MI, and revascularization rates. The reasons for this finding need to be better understood, including the possible role of low medication adherence rates that have been found in other studies.

Entities:  

Mesh:

Year:  2012        PMID: 22441935     DOI: 10.1161/CIRCULATIONAHA.111.071811

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Treating stable ischemic heart disease with percutaneous coronary intervention - The debate continues.

Authors:  Rishi Puri; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2012-12

Review 2.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

3.  Economic utility of a blood-based genomic test for the assessment of patients with symptoms suggestive of obstructive coronary artery disease.

Authors:  Louis I Hochheiser; Jessie L Juusola; Mark Monane; Joseph A Ladapo
Journal:  Popul Health Manag       Date:  2014-02-25       Impact factor: 2.459

4.  Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: a population-based study.

Authors:  Harindra C Wijeysundera; Maria C Bennell; Feng Qiu; Dennis T Ko; Jack V Tu; Duminda N Wijeysundera; Peter C Austin
Journal:  J Gen Intern Med       Date:  2014-03-08       Impact factor: 5.128

5.  Association between the Availability of Hospital-based Palliative Care and Treatment Intensity for Critically Ill Patients.

Authors:  May Hua; Xiaoyue Ma; R Sean Morrison; Guohua Li; Hannah Wunsch
Journal:  Ann Am Thorac Soc       Date:  2018-09

6.  Early and late unplanned rehospitalizations for survivors of critical illness*.

Authors:  May Hua; Michelle Ng Gong; Joanne Brady; Hannah Wunsch
Journal:  Crit Care Med       Date:  2015-02       Impact factor: 7.598

Review 7.  Recent insights into the treatment of stable CAD : FFR-guided PCI vs. medical therapy.

Authors:  L X van Nunen; P A L Tonino
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

Review 8.  Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Authors:  Gregg W Stone; Judith S Hochman; David O Williams; William E Boden; T Bruce Ferguson; Robert A Harrington; David J Maron
Journal:  J Am Coll Cardiol       Date:  2015-11-23       Impact factor: 24.094

9.  Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE and FAME 2 trials.

Authors:  M T Torosoff; M S Sidhu; W E Boden
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

10.  The effect of percutaneous coronary revascularization on plasma N-terminal pro-B-type natriuretic peptide levels in stable coronary artery disease.

Authors:  Amit Gupta; Jahangir Rashid Beig; Nisar A Tramboo; Dil Afroze; Imran Hafeez; Hilal A Rather
Journal:  Indian Heart J       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.